Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - Cerevel Therapeutics Holdings, Inc. | brhc10013955_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - Cerevel Therapeutics Holdings, Inc. | brhc10013955_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - Cerevel Therapeutics Holdings, Inc. | brhc10013955_ex31-1.htm |
| 10-Q - 10-Q - Cerevel Therapeutics Holdings, Inc. | brhc10013955_10q.htm |
EXHIBIT 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of ARYA Sciences Acquisition Corp II (the “Company”) on Form 10-Q for the quarter ended June 30, 2020, as filed with the Securities and Exchange
Commission on the date hereof (the “Report”), I, Michael Altman, Chief Financial Officer and Director of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to
my knowledge:
| (1) |
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
| (2) |
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Date: August 14, 2020
|
/s/ Michael Altman
|
||
|
Name:
|
Michael Altman
|
|
|
Title:
|
Chief Financial Officer and Director
|
|
|
(Principal Financial and Accounting Officer)
|
||